Serum High Sensitivity CRP (HsCRP) in Psoriasis
Keywords:
Dyslipidemia, Psoriasis, hsCRP, Coronary artery disease
Abstract
Introduction: Psoriasis is a common and recurrent proliferative inflammatory skin disease that has been associated with abnormal plasma lipid metabolism and with high frequency of cardiovascular morbidity and mortality. Dyslipidemia in psoriatic patients make them more prone for CAD. Highly sensitive C reactive protein (HsCRP) is a recent and sensitive marker of the inflammation particularly in atherosclerotic changes. So the levels of hsCRP and lipid profile were evaluated in psoriatic patients.
Material and Methods: The study included 35 psoriatic patients and 35 healthy age and sex matched controls. Both the groups were evaluated for serum lipid profile and HsCRP levels.
Results: The study showed that there was a significant rise in the levels of hsCRP in patients of psoriasis as compared to the controls (p<0.001) These psoriatic patients were also significantly dyslipidemic as compared to the controls.
Conclusion: The study showed that psoriatic patients are more prone for atherosclerotic changes and CAD. Raised hsCRP can be considered as an added risk factor in Psoriatic patients with regard to coronary artery diseases. Special attention thus should be given if diagnosed earlier for lifestyle modification and exercise in these patients to minimize the atherosclerotic changes. Role of antioxidant supplementation needs further studies in patients of psoriasis.
Downloads
Download data is not yet available.
References
1. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008 Dec 15;102(12):1631-43. [PubMed]
2. Van de Kerkhof PCM. The evolution of the psoriatic lesion. Br JDermatol 2007: 157:4 –15. [PubMed]
3. Schon MP, Boehncke W-H. Psoriasis. N Engl J Med 2005;352:1899–1912. [PubMed]
4. Krueger JG, Bowcock A. Psoriasis pathophysiology: current conceptsof pathogenesis. Ann Rhuem Dis 2005;64:ii30 –ii36. [PubMed]
5. Griffiths CE, Barker JNW. Pathogenesis and clinical features of psoriasis. Lancet 2007: 360:263–271. [PubMed]
6. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC,Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207–1211. [PubMed]
7. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG,. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58: 1031–1042. [PubMed]
8. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303:33–39. [PubMed]
9. Neimann AI, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829–835. [PubMed]
10. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614–621. [PubMed]
11. Ridker PM. A Simple Test to Help Predict Risk of Heart Attack and Stroke.Circulation.2003;107:363-369. [PubMed]
12. Prodanovich S, Kirsner RS, K revetez JD Association of Psoriasis with coronery artery disease, cerebrovascular & peripheral vascular disease & mortality. Arch Dermatol. 2009: 20(470)197413.
13. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004:351:2599 –2610. [PubMed]
14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl JMed. 1997:336:973–979. [PubMed]
15. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002:106; 3143–21.
16. Denka S. Evaluation of a Turbidimetric C-Reactive Protein Assay for Cardiovascular Risk Estimation and Conventional Inflammation Diagnosis. Clin. Chem. 2003: 49: 511-512. [PubMed]
17. Myers G, L Kimberly M. A reference method laboratory network for cholesterol : a model for standardisation and improvement of clinical laboratory measurement. Clin Chem. 2000:46: 1762~ 1772.
18. Henry JB. Clinical diagnosis and management of laboratory methods. 18th edition :W.B. Saunders Philadelphia, 204~211.
19. Greg Miller W. Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures Clinical Chemistry .2010, 56: 977-986.
20. Kurd SK, Richardson S, Gelfand JM. Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol. 2007; 3:171–185. [PubMed]
21. Cohen AD, Sherf M, Vidavsky L. Association between psoriasis and the metabolic syndrome. Dermatol. 2008; 216:152–155. [PubMed]
22. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007; 21:1330–1332. [PubMed]
23. Dreiher J, Weitzman D, Davidovic D, Shapiro J, Arnon DC. Psoriasis and Dyslipidaemia: A Population based Study. Acta Derm Venereol. 2008; 88: 561–565. [PubMed]
24. Susan JM, Molly CC, Hal K, John DB, John JA. Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution. J Lipid Res. 2002: 43: 1256-1263.
25. Yiu KH, Yeung CK, Chan HT, Wong RMY, Tam S, Lam KF, Yan GH, Yue WS, Chan HH, Tse HF. Increased Arterial Stiffness in Patients with Psoriasis is Associated with Active Systemic Inflammation. The British Journal of Dermatology. 2011;14(3):514-520.
26. Agravatt AM, Sirajwala HB. A Study of serum hsCRP levels to assess severity in patients with Psoriasis. IJBAR. 2013: 04 (07)460-466.
27. Wasunna A. CRP and bacterial infections in preterm infants. Eur .J of aed.1990:149;424-7.
28. Gelfand JM, Troxel A, Lewis JD. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007: 143:1493–1498.
29. Sommer DM, Jenisch S, Suchan M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006: 298:321–328.
2. Van de Kerkhof PCM. The evolution of the psoriatic lesion. Br JDermatol 2007: 157:4 –15. [PubMed]
3. Schon MP, Boehncke W-H. Psoriasis. N Engl J Med 2005;352:1899–1912. [PubMed]
4. Krueger JG, Bowcock A. Psoriasis pathophysiology: current conceptsof pathogenesis. Ann Rhuem Dis 2005;64:ii30 –ii36. [PubMed]
5. Griffiths CE, Barker JNW. Pathogenesis and clinical features of psoriasis. Lancet 2007: 360:263–271. [PubMed]
6. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC,Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207–1211. [PubMed]
7. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG,. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58: 1031–1042. [PubMed]
8. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303:33–39. [PubMed]
9. Neimann AI, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829–835. [PubMed]
10. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614–621. [PubMed]
11. Ridker PM. A Simple Test to Help Predict Risk of Heart Attack and Stroke.Circulation.2003;107:363-369. [PubMed]
12. Prodanovich S, Kirsner RS, K revetez JD Association of Psoriasis with coronery artery disease, cerebrovascular & peripheral vascular disease & mortality. Arch Dermatol. 2009: 20(470)197413.
13. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004:351:2599 –2610. [PubMed]
14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl JMed. 1997:336:973–979. [PubMed]
15. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002:106; 3143–21.
16. Denka S. Evaluation of a Turbidimetric C-Reactive Protein Assay for Cardiovascular Risk Estimation and Conventional Inflammation Diagnosis. Clin. Chem. 2003: 49: 511-512. [PubMed]
17. Myers G, L Kimberly M. A reference method laboratory network for cholesterol : a model for standardisation and improvement of clinical laboratory measurement. Clin Chem. 2000:46: 1762~ 1772.
18. Henry JB. Clinical diagnosis and management of laboratory methods. 18th edition :W.B. Saunders Philadelphia, 204~211.
19. Greg Miller W. Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures Clinical Chemistry .2010, 56: 977-986.
20. Kurd SK, Richardson S, Gelfand JM. Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol. 2007; 3:171–185. [PubMed]
21. Cohen AD, Sherf M, Vidavsky L. Association between psoriasis and the metabolic syndrome. Dermatol. 2008; 216:152–155. [PubMed]
22. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007; 21:1330–1332. [PubMed]
23. Dreiher J, Weitzman D, Davidovic D, Shapiro J, Arnon DC. Psoriasis and Dyslipidaemia: A Population based Study. Acta Derm Venereol. 2008; 88: 561–565. [PubMed]
24. Susan JM, Molly CC, Hal K, John DB, John JA. Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution. J Lipid Res. 2002: 43: 1256-1263.
25. Yiu KH, Yeung CK, Chan HT, Wong RMY, Tam S, Lam KF, Yan GH, Yue WS, Chan HH, Tse HF. Increased Arterial Stiffness in Patients with Psoriasis is Associated with Active Systemic Inflammation. The British Journal of Dermatology. 2011;14(3):514-520.
26. Agravatt AM, Sirajwala HB. A Study of serum hsCRP levels to assess severity in patients with Psoriasis. IJBAR. 2013: 04 (07)460-466.
27. Wasunna A. CRP and bacterial infections in preterm infants. Eur .J of aed.1990:149;424-7.
28. Gelfand JM, Troxel A, Lewis JD. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007: 143:1493–1498.
29. Sommer DM, Jenisch S, Suchan M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006: 298:321–328.
CITATION
DOI: 10.17511/ijmrr.2014.i05.02
Published: 2014-10-31
How to Cite
1.
Dhat V, Murhe S, Sontakke A. Serum High Sensitivity CRP (HsCRP) in Psoriasis. Int J Med Res Rev [Internet]. 2014Oct.31 [cited 2024Nov.8];2(5):409-13. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/131
Section
Original Article
OAI - Open Archives Initiative
